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The  capacity  of  carboxymethyl  starch  (CMS):Chitosan  monolithic  tablets  to protect  diamine  oxidase
and/or  catalase  therapeutic  enzymes  against  simulated  gastric  ﬂuid  (SGF)  and  to  control  their  deliv-
ery  in  simulated  intestinal  ﬂuid  (SIF)  was  investigated.  Enzyme  formulations  loaded  with  grass  pea
seedlings  diamine  oxidase  (PSDAO)  vegetal  extract,  catalase,  or PSDAO  associated  to  catalase,  were
obtained  by  direct  compression.  The  CMS:Chitosan  (1:1)  matrix  afforded  a good  gastric  protection  to
PSDAO  and  to catalase,  when  each  enzyme  was  formulated  separately.  Variable  amounts  of  DAO  were
delivered  in the  SIF  containing  pancreatin,  with  maximal  release  reached  at about 8 h, a time  conve-atalase




nient  for  tablets  to  attain  the  colon.  Up  to  50%  of  the  initial  enzymatic  activity  of  catalase  formulated
with  CMS:Chitosan  was  found  after  8  h in  SIF.  For  the  CMS:Chitosan  tablets  of  bi-enzymatic  formulations
containing  PSDAO:Catalase,  the  releases  of  DAO  and  of  catalase  were  synchronized.  The  hydrogen  per-
oxide  (product  of  DAO  activity)  was  decomposed  by  the  catalase  liberated  in  the  same  SIF  environment.
The  proposed  formulations  could  allow  novel  therapeutic  approaches  for the  treatment  of inﬂammatory
bowel  diseases,  intestinal  cancers  or pseudo-allergic  reactions.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction
The diamine oxidase (DAO, EC 1.4.3.6), also called histaminase
Mondovi et al., 1964), catalyzes the oxidative deamination of his-
amine and other biogenic amines (Mondovi et al., 1989), with the
elease of the corresponding aldehydes, hydrogen peroxide (H2O2)
nd ammonia (NH3). As previously shown with other copper oxi-
ases, such as ceruloplasmin and bovine serum amine oxidase
ith antioxidant, cardioprotective and antiﬁbrillatory properties
Atanasiu et al., 1995; Mateescu et al., 1997; Mateescu and Nadeau,
009; Mondovi et al., 1997), a vegetal DAO, with an enzymatic
ctivity higher than that of the animal one, presents some bene-
cial effects in cardiac anaphylactic response (Masini et al., 2002),
Abbreviations: CMS, carboxymethyl starch; GDH, l-glutamate dehydrogenase;
BD,  inﬂammatory bowel disease; KGA, alpha-ketoglutaric acid; MW,  molecular
eight;  NADPH, nicotinamide adenine dinucleotide phosphate; OCT, Organic Cation
ransporter; OPDA, ortho-phenylenediamine dihydrochloride; PSDAO, grass pea
eedlings diamine oxidase; SGF, simulated gastric ﬂuid; SIF, simulated intestinal
uid.
∗ Corresponding  author. Tel.: +1 514 987 4319; fax: +1 514 987 4054.
E-mail  address: mateescu.m-alexandru@uqam.ca (M.A. Mateescu).
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Open access under CC BY-NC-ND license.in myocardial ischemia and reperfusion injury (Masini et al., 2003)
and in the treatment of asthma-like reaction (Masini et al., 2004).
Recently, Masini et al. (2007) showed that pea seedling DAO,
when parenterally administered, may  have protective effects on
intestinal ischemia, by reducing local tissue inﬂammation and by
counteracting free radical-mediated tissue injury.
The DAO is the main histamine degrading enzyme acting pre-
dominantly in the intestinal tract which may protect against
the endogenous (Beaven, 1982) or exogenous (food) histamine
(Taylor, 1986). Food-induced histaminosis can generate plasma his-
tamine elevation and hemodynamic alterations, particularly when
associated with low DAO activity (Sattler et al., 1988). A high
histamine content in some food can become toxic, especially in
oriental food (Chin et al., 1989). Elevated histamine content in
food and beverages can also be associated to microbial contam-
ination (Bodmer et al., 1999). The mechanism of pseudo-allergic
reactions of histamine caused by food seems to be mainly ascribed
to an intestinal hyperpermeability (caused by irritant species as
alcohol) or by decrease of DAO enzymatic activity. Since DAO is a
major catabolic enzyme for histamine in humans, its lower level
at the sites of mucosal inﬂammation would generate an accu-

































































The powder of Chitosan was  prepared as previously described
(Calinescu and Mateescu, 2008), by dissolving the purchased Chi-C. Calinescu et al. / International Jou
nﬂammatory responses (Owen, 1987). Thus, in the pathogene-
is of inﬂammatory bowel disease (IBD), mucosal alterations are
requently related to changes of mucosal DAO activity and, respec-
ively, in mucosal histamine content (Fox et al., 1990). In areas of
acroscopically inﬂamed tissue in IBD, the DAO activity was  found
ower than in normal intestinal tissues (Schmidt et al., 1990). Fur-
hermore, the jejunal secretion of histamine was reported as higher
n Crohn’s disease and was signiﬁcantly correlated with the Crohn’s
isease activity index (Knutson et al., 1990). During intestinal post-
schemic reperfusion, it was found a marked histamine release by
he intestinal mucosa, and the activity of DAO was  signiﬁcantly
educed (Kusche et al., 1981). High histamine content was  also
ound in experimental neoplasias, such as colon carcinomas (Cricco
t al., 1994), and a direct relationship between DAO activity and
umor progression was shown (Kusche et al., 1988). Antitumoral
ffects were described for pig kidney DAO (Mondovi et al., 1982)
nd for amine oxidases (Toninello et al., 2006).
The information concerning the therapeutical effects of DAO on
BD is rather limited. Fogel and Lewinski (2006) showed a possible
herapeutic effect of hog kidney DAO, administered intraperi-
oneally, on a model of ulcerative colitis in rat, with a reduction
f inﬂammatory reaction. Decreasing the histamine levels and the
xidative stress in intestinal inﬂammation could be a promising
herapeutic strategy to better manage the IBD. As for most oxidases,
 by-product of the DAO enzymatic reaction is H2O2, a pro-oxidant
gent which can present desirable bactericidal and undesirable
xidative damaging effects. Catalase (EC 1.11.1.6) is an antioxi-
ant enzyme that speciﬁcally catalyzes the decomposition of H2O2.
ue to its H2O2 decomposition capacity, catalase was proposed for
se in post-ischemic reperfusion injury in myocardial infarction
nd stroke, burns, trauma (Phillips and Snow, 1994), as parenteral
ormulations of the enzyme covalently bound to polyethylene gly-
ol.
We are now proposing an oral enzymatic therapy based on
SDAO associated with catalase for the treatment of various colon
iseases. The PSDAO would control the levels of histamine and
ould have some antioxidant effects. When associated, catalase
ill particularly eliminate the H2O2 by-product of DAO, preventing
he local intestinal oxidative stress. It was recently found that H2O2
an inhibit copper amine oxidases and that the catalase protects
mineoxidases from inactivation by produced H2O2 (Pietrangeli
t al., 2004). In our case, associated catalase not only will pro-
ect PSDAO, but, in addition, could generate more oxygen (O2), a
ubstrate of PSDAO, enhancing its efﬁciency.
A major challenge of oral pharmaceutical forms is to deliver
ioactive agents to colon without gastric or intestinal degrada-
ion during the gastro-intestinal transit of the oral dosages, and
his fact constitutes an important step for our proposed therapy. As
olonic microﬂora produce a large number of degrading enzymes,
everal natural polysaccharides from algal (alginates), plant (pectin,
uar gum), microbial (dextran, xanthan gum) or animal origin
chondroitin), have been investigated as carriers for colon-speciﬁc
rug delivery. Chitosan, a poly -(1,4)-linked 2-amino-2-deoxy-
-glucose, insoluble at the pH of intestinal ﬂuids, appears as an
nteresting excipient for site-speciﬁc delivery to the colon due to its
usceptibility to glycosidic hydrolysis by microbial enzymes in the
olon (Zhang and Neau, 2002). The association of cationic Chitosan
ith other biodegradable polymers, such as anionic CMS  (Calinescu
t al., 2005, 2007), could also represent an interesting way to deliver
ioactive agents to the colon. Recently, monolithic tablets based on
MS:Chitosan excipients were proposed for colon delivery of small
olecules (Leonida and Mateescu, 2006) and probiotics (Calinescu
nd Mateescu, 2008). The aim of this study was  to investigate the
otential of CMS:Chitosan matrix to protect the enzymes PSDAO
nd/or Catalase against simulated gastric conditions and to delay
heir delivery in simulated intestinal conditions.f Pharmaceutics 428 (2012) 48– 56 49
2. Materials and methods
2.1. Materials
High amylose starch (Hylon VII) was obtained from National
Starch (Bridgewater, NJ, USA) and Chitosan (600 kDa, 92% degree
of deacetylation) from Marinard Biotech (Rivière-au-Renard, Qc,
Canada). Bromocresol green (sodium salt), 1,4-diaminobutane
dihydrochloride (putrescine), ortho-phenylenediamine dihy-
drochloride (OPDA), horseradish peroxidase (type I, 96
purpurogallin enzyme units/mg solid), ammonia assay kit,
hydrogen peroxide (30%), Folin-Ciocalteu Reagent, pepsin (from
porcine gastric mucosa: 882 units/mg protein), pancreatin (from
porcine pancreas, USP speciﬁcations) and catalase (from bovine
liver: 2950 units/mg solid; 4540 units/mg protein) were purchased
from Sigma–Aldrich Chemical Company (St. Louis, MO,  USA). The
other chemicals were reagent grade and used without further
puriﬁcation.
2.2. Preparation of diamine oxidase vegetal extract from
seedlings of Lathyrus sativus (grass pea)
The PSDAO was obtained from 500 g of freshly collected shoots
of etiolated L. sativus seedlings which were homogenized in a War-
ing blender with 1 L of 30 mM NaH2PO4 (ﬁnal pH 4.4), and then
ﬁltered. The solid residue, mainly constituted by cell walls and vas-
cular ﬁbers, was washed with the same buffer and the enzyme was
ﬁnally eluted from the solid residue with 500 mL  of 0.1 M sodium
phosphate buffer (pH 7) and, then, centrifuged. The supernatant
containing the DAO was lyophilized, obtaining thus the DAO vegetal
extract powder, hereto called PSDAO.
2.3. Carboxymethyl high amylose starch excipient synthesis
The CMS  excipient was synthesized in alkaline medium,
as previously described (Calinescu et al., 2005, 2007), using
monochloroacetic acid as starch substitution agent. Practically, an
amount of 70 g high amylose starch (Hylon VII) was suspended in
170 mL  of distilled water and warmed at 50 ◦C under continuous
stirring in a Hobart planetary mixer. A volume of 235 mL  of an aque-
ous 1.45 M NaOH solution was added and the reaction medium was
homogenized for 20 min  at 50 ◦C for gelatinization. To transform
the starch into a more reactive alkoxide form (and thus favorising
the starch nucleophilic substitution), 55 mL  of 10 M NaOH solu-
tion were also added to the reactional medium. Then, 45.5 g of
monochloroacetic acid, rapidly dissolved in a minimal volume of
water, were added to the starch and the reactional medium was
kept for 1 h at 50 ◦C for the reaction of substitution. After 1 h, the
gel-slurry was  neutralized with an acetic acid solution and pre-
cipitated with acetone, and the salt ions were removed by several
repeated washings with acetone/water (60:40, v/v). Finally, the
CMS gel-slurry was  dried with acetone and kept overnight at room
temperature.
The polymer powder was then sieved and particles with granu-
lometry less than 300 m were retained for the formulation study.
Fourier transform infrared spectroscopy was  used to detect the
presence of newly introduced carboxymethyl groups. The degree
of substitution was determined by direct titration as previously
described (Calinescu et al., 2005).
2.4. Preparation of Chitosan excipienttosan in an acetic acid solution (2%), followed by its ﬁltration (to



















































10 C. Calinescu et al. / International Jou
o the homogeneous ﬁltrate until a pH of 6.5. The gel-slurry was
recipitated with 100% acetone, thoroughly washed with distilled
ater, and ﬁnally dried at room temperature. Excipient fraction
maller than 300 m was retained for the preparation of monolithic
ablets.
.5. Fabrication of monolithic tablets
The powders of CMS  and/or Chitosan excipients were well
ixed with the bioactive agents (PSDAO and/or catalase pow-
ers) until homogenization. Flat-faced tablets of 300 mg  were
btained by direct compression (2.5 T) of the powder mixtures
sing 9 mm cylinder outﬁts and a Carver press (Wabash, IN, USA).
he PSDAO powder (30% loading) was formulated with CMS  alone,
MS:Chitosan (1:1, w/w) or Chitosan alone. Catalase (3.3%, 10%,
0%, 50% loading) was formulated only with CMS:Chitosan (1:1,
/w). Tablets based on 100% enzymes (excipient-free) were also
roduced as control. Bi-enzymatic monolithic tablets, based on
MS:Chitosan (1:1, w/w) and containing both enzymes (PSDAO and
atalase), were also realized with a constant loading of PSDAO (20%)
nd a variable loading of catalase (10% and 20%) per tablet.
.6. Gastric stability of tablet formulations (with or without
SDAO or catalase)
Tablets of 300 mg,  based on CMS:Chitosan (1:1) with 0% and
0% enzyme loading or on 100% enzyme (without excipients), and
oaded with 5% bromocresol green (15 mg  pH indicator per tablet),
ere prepared as previously described. Each tablet was incubated
0 min  in 50 mL  of SGF containing 0.32% pepsin (USP, 2009) at 37 ◦C
nd 50 rpm (incubator shaker, series 25D, New Brunswick Scien-
iﬁc Co., NJ, USA). The tablet integrity and color modiﬁcations were
oticed on the whole and on cross-sectioned tablets.
.7. Stability of enzyme formulations in simulated gastric ﬂuid
Tablets based on CMS  alone, CMS:Chitosan (1:1) or Chitosan
lone (as excipients), containing 30% PSDAO (as active principle
ngredient), were incubated for 0, 30, 60, 120 min  in 50 mL  SGF, pH
.2, with 0.32% pepsin (USP, 2009), at 37 ◦C and 50 rpm using the
ncubator shaker as before. Also, the CMS:Chitosan formulations
ontaining catalase only (different loadings) or the two  enzymes
PSDAO:Catalase) were incubated for 60 min  in SGF (in the same
onditions as before). The remaining enzymatic activities in the
ablets were determined after the incubation times indicated above
y crushing the tablets in 50 mL  of 50 mM potassium phosphate
uffer (pH 7.0), followed by sample ﬁltration.
.8. Enzyme delivery in simulated intestinal ﬂuid
The tablet formulations containing PSDAO only, catalase only or
he two enzymes were ﬁrst incubated in SGF for the same incu-
ation times indicated above. After SGF incubation, tablets were
ndividually transferred into 50 mL  SIF, pH 6.8, with 1% pancreatin
USP, 2009) and incubated at 37 ◦C and 50 rpm (total dissolution
ime of 24 h), using the same incubator shaker. Samples of 1 mL
ere taken from SIF after regular intervals of time, ﬁltered and
he DAO and catalase enzymatic activities were determined (as
escribed at Section 2.10).
.9. Evaluation of DAO enzymatic activity in the presence of
atalase
PSDAO:Catalase powders at different weight ratios (6:1, 2:1,
:1) were dissolved in 50 mL  phosphate buffer solution (50 mM,  pHf Pharmaceutics 428 (2012) 48– 56
7.0), kept 120 min under agitation at 4 ◦C and ﬁltered prior to deter-
mine the DAO enzymatic activity in the absence or in the presence
of catalase.
2.10. Determination of DAO enzymatic activity
(a) Enzymatic assay of DAO with the peroxidase coupled reac-
tion (speciﬁc for released H2O2). The DAO enzymatic activity was
spectrophotometrically assayed with a peroxidase coupled reac-
tion, in the same conditions as previously described (Calinescu
et al., 2010). Brieﬂy, the reactional mixture containing 640 L of
50 mM potassium phosphate buffer (pH 7.0), 10 L of peroxidase
solution (0.1 mg/mL), 50 L of 30 mM  OPDA solution and 200 L
of 30 mM  putrescine solution was  incubated for 5 min  at 37 ◦C
and then, 100 L of DAO samples were added to start the dosage.
The enzymatic reactions were conducted at 37 ◦C for 10 min, when
100 L of HCl (4 M)  were added and the ﬁnal absorbance was read
at 484 nm using a Beckman DU®-6 spectrophotometer. The stan-
dard curve was prepared with serial concentrations of H2O2 from
0 to 68 M.
(b) Enzymatic assay of DAO with the l-glutamate dehydro-
genase (GDH) coupled reaction (speciﬁc for released NH3). In
particular case of the association of DAO with catalase, the DAO
assay via peroxidase cannot apply due to decomposition of H2O2 by
the associated catalase. For these cases, the DAO enzymatic activity
was  also evaluated using an ammonia assay kit (Sigma–Aldrich),
where NH3 released from the putrescine substrate (under DAO
catalysis) reacts with alpha-ketoglutaric acid (KGA) and reduced
nicotinamide adenine dinucleotide phosphate (NADPH) in the
presence of GDH. The reactional mixture containing 1 mL  of assay
kit reagent (KGA and NADPH), 200 L of 30 mM putrescine solu-
tion, 10 L of GDH (kit reagent) was  incubated for 5 min  at 37 ◦C
and, ﬁnally, 100 L of DAO samples (containing or not catalase)
were added. The enzymatic reactions were conducted at 37 ◦C for
10 min, monitoring the decrease of absorbency at 340 nm. Since
catalase also strongly binds NADPH in its active center, the cata-
lase interference was  subtracted from each determination of DAO
enzymatic activity.
One enzymatic unit (EU) of DAO was deﬁned as the amount
of enzyme catalyzing the oxidation of 1.0 mole of putrescine per
10 min  at pH 7.0 and 37 ◦C.
For CMS, CMS:Chitosan (1:1) and Chitosan formulations con-
taining 30% PSDAO only, the DAO enzymatic activity was
determined by the peroxidase coupled assay.
For the formulations based on CMS:Chitosan (1:1) and contain-
ing 20% PSDAO and different loadings in catalase (0%, 10% and 20%),
the DAO enzymatic activity was  determined by the peroxidase cou-
pled assay and by the GDH coupled assay.
The DAO enzymatic activity of vegetal extract powder (PSDAO)
and of different weight ratios of PSDAO:Catalase powders, was also
evaluated by the two enzymatic reactions, as proposed before.
2.11. Determination of catalase enzymatic activity
The enzymatic activity of catalase was determined spectropho-
tometrically (Beckman DU®-6) by monitoring at 240 nm the H2O2
decrease during catalysis (Claiborne, 1985). The reactional medium
contained: 2.9 mL  of H2O2 (0.036%) prepared in 50 mM potassium
phosphate buffer (pH 7.0) and 0.1 mL  of ﬁltered sample containing
catalase.
One enzymatic unit (EU) of catalase is deﬁned as the amount of
enzyme decomposing 1.0 mole of H2O2 per minute at pH 7.0 and
21 ◦C, while the H2O2 concentration falls from 10.3 mM to 9.2 mM.
Protein concentrations of the PSDAO and of catalase powders
were determined by the method of Lowry et al. (1951),  using bovine
serum albumin as standard.
C. Calinescu et al. / International Journal o
Fig. 1. pH stability of enzyme formulations in tablets based on CMS:Chitosan. Mono-
lithic tablets based on (a) CMS:Chitosan (1:1) with 0% and 50% enzyme loading and
on  excipient-free 100% diamine oxidase vegetal extract (PSDAO) or (b) catalase, con-
taining bromocresol green (pH indicator). Untreated (air) or incubated tablets for





























ous incubation in SGF. When incubated directly in SIF, the absenceross-sections of tablets). The blue color indicates protection against gastric acidity.
ubstitution degree of CMS: 0.126.
. Results and discussion
.1. Gastric stability of tablet formulations (with or without
SDAO or catalase)
The hydrophilic matrix based on binary mixtures of
MS:Chitosan (1:1), in which both macromolecular excipients
ontribute to a physical and chemical stabilization of the dosage
orm (Calinescu and Mateescu, 2008; Leonida and Mateescu, 2006),
eems a good system for the formulation of orally administrable
herapeutic proteins, such as PSDAO and catalase. To evaluate the
H within the tablets, the test with a pH indicator is useful because
t indicates in which extent the excipients can protect the active
gent(s) in SGF following the color change of the pH indicator (i.e.,
or bromocresol green pH indicator, the color changes from blue,
ver pH 5.4, to yellow-orange, below pH 3.8). Thus, to the air,
efore incubation in SGF, the dry tablets based on CMS:Chitosan
1:1) unloaded (0%) and loaded with 50% PSDAO or with catalase,
nd the tablets based on 100% enzyme (PSDAO or catalase) pre-
ented some blue points at the external surface, corresponding
o the pH indicator (Fig. 1a, b). The surface of the entire tablets
ased on CMS:Chitosan excipients (with 0% and 50% enzyme
oading) was blue during the 60 min  of acidic incubation (SGF). The
MS:Chitosan matrix forms an outer gel barrier, affording thus
 certain protection against gastric acidity, despite the fact that
he tablets are not coated with gastro-protective materials. At the
urface of the whole tablets, some small orange regions were also
etected, corresponding to a certain presence of acidity (mostly
imited at the very outer layer).f Pharmaceutics 428 (2012) 48– 56 51
The CMS:Chitosan formulations with PSDAO only were less
stable at 50% loading and unstable when formulated without
CMS:Chitosan (100% PSDAO). Thus, the excipient-free formulation,
based on 100% PSDAO only, was rapidly disintegrated and dissolved
during the incubation in SGF medium. This lower stability of PSDAO
tablet could be related to a certain amount of phosphate in the
powder extract remaining after the preparation procedures. On the
other hand, the presence of hydrophilic phosphate in PSDAO prepa-
ration can be an advantage for formulation, ensuring the tablet
hydration and the release of loaded enzyme.
Differently, the excipient-free tablets, based on 100% cata-
lase, were compact after the SGF incubation, with no tendency
of swelling nor disintegration, but exhibiting an orange external
surface of the tablets, showing lesser protection in acidic medium.
When the tablets were cross-sectioned, the core of the tablets was
dry, with no gastric ﬂuid inside the tablets and, consequently, no
solubilization of the bromocresol green particles. Furthermore, a
peripheral blue layer (pH greater than 5.4) close to the surface of the
tablets was  found (Fig. 1a, b). Thus, the presence of the proteins in
the formulations may  also contribute to gastro-protection, as found
for catalase at loading of 50% and 100%. These aspects are useful and
important for further enzyme formulations, showing that not only
the CMS:Chitosan excipients afforded a certain gastro-protection of
bioactive agents, but protein itself can generate an outer protective
gel layer keeping dry the core of the tablets.
3.2. Stability of enzyme formulations in simulated gastric ﬂuid
and enzyme delivery in simulated intestinal ﬂuid
The PSDAO was  found as very sensitive to gastric acidity and
to pepsinolysis, loosing its entire enzymatic activity in less than
15 min  of incubation, either in the presence or absence of pepsin.
Differently, the DAO maintains a certain stability at proteolysis to
pancreatin (Calinescu et al., 2010), and this is an important aspect
for further therapeutic applications of the enzyme when released
in intestinal ﬂuids.
Formulations based on CMS, CMS:Chitosan (1:1) or Chitosan and
containing 30% PSDAO presented a certain stability in SGF condi-
tions (pH 1.2, pepsin) during the whole periods of incubation. After
60 min  of gastric treatment, CMS:Chitosan (1:1) and Chitosan for-
mulations afforded a better protection of DAO than CMS (Fig. 2a)
and after 120 min  of incubation, the CMS:Chitosan matrix pre-
sented a better efﬁcacy in term of protection of PSDAO, with a 55.5%
remaining DAO activity found inside the tablet (Fig. 2a). Thus, the
CMS:Chitosan matrix could present a potential interest, ensuring a
good protection of the DAO even after 120 min incubation in SGF,
with maximal release of therapeutic enzyme in SIF at about 8 h
(enough for tablets to reach the colon). The release of bioactive
agent can be controlled by an adequate choice of the amount and
of the molecular weight of Chitosan in the tablet (Calinescu and
Mateescu, 2008). Thus, for the Chitosan of 600 kDa (the present
study), a delay in the DAO liberation was already observed after
30 min  of gastric incubation of CMS:Chitosan (1:1) tablets com-
pared to those based on CMS  matrix only, which released rapidly
the bioactive agent in SIF. In the case of CMS, the release time can
be modulated by alpha-amylase from pancreatin, which can still
act on CMS  excipient (Calinescu et al., 2005). This is an important
advantage of CMS  as excipient. The tablets based on CMS only are
not suitable for colon delivery because of their fast dissolution in
SIF medium containing pancreatin.
For better understanding of mechanisms controlling the DAO
release, the tablets were also incubated in SIF only, without previ-of the external gel of Chitosan generated a faster liberation of DAO
for CMS:Chitosan and Chitosan formulations (Fig. 2b) in compari-
son with the same formulations previously incubated in SGF (30, 60,
52 C. Calinescu et al. / International Journal of Pharmaceutics 428 (2012) 48– 56
Fig. 2. Gastric stability and intestinal delivery of vegetal diamine oxidase (PSDAO)
in  different formulations. Monolithic tablets based on CMS  (substitution degree:
Fig. 3. Gastric stability and intestinal release of catalase at different loadings formu-
lated with CMS:Chitosan. Monolithic tablets of CMS:Chitosan (1:1) with increasing
loading of catalase and of excipient-free (100%) catalase were ﬁrst incubated for
60  min  in simulated gastric ﬂuid (SGF with pepsin) at 50 rpm and 37 ◦C. Substitu-
tion  degree of CMS: 0.126. The enzymatic activity of catalase (%) was evaluated (a)
after 60 min  of gastric incubation of tablets and (b) during the liberation in simu-
lated intestinal ﬂuid (SIF with pancreatin), after previous incubation of 60 min  in
SGF. Catalase activity was expressed in percentage, considering for each loading,
as  100%, the catalase activity formulated with CMS:Chitosan determined in 50 mL
phosphate buffer at 0 min. n = 3.
120 min), where the outer gel delayed the DAO delivery (Fig. 2c–e).
The formulation based on CMS:Chitosan (1:1) presented a better
delivery of DAO than the Chitosan formulation (Fig. 2b–e). In an
acidic environment, Chitosan tablets form gels (Wang et al., 2011)
due to their amino groups, contributing to the protection of active
agent and, at the same time, allowing its slow-release. Wang et al.
(2011) realized a study of Nuclear Magnetic Resonance imaging on
monolithic tablets of Chitosan showing the formation of a transpar-
ent gel thick layer around the hard core. The size of the tablet core
decreased gradually with time, and no proton signal was detected
in the dry core during the process, as shown by the clear-cut fea-
ture of the proton density proﬁle (Wang et al., 2011). This gel layer
formed in an acidic medium contributes to delay the liberation of
DAO from Chitosan and CMS:Chitosan monolithic tablets.
The second therapeutic enzyme used in this study, catalase,
was  ﬁrst formulated alone with CMS:Chitosan (1:1) at different
loadings. It was observed that, at increasing catalase loading from
0.126), CMS:Chitosan (1:1) or Chitosan and containing 30% PSDAO were incubated
up  to 120 min  in simulated gastric ﬂuid (SGF with pepsin). (a) DAO remaining enzy-
matic activity (%) inside the tablets, as determined after different periods of SGF
treatment. The liberation of DAO (%) from monolithic tablets in simulated intestinal
ﬂuid (SIF with pancreatin) after (b) 0 min, (c) 30 min, (d) 60 min  and (e) 120 min
of  SGF incubation (50 rpm and 37 ◦C). The DAO activity is expressed in percent-
ages, considering as 100% the values determined in 50 mL phosphate buffer at
0  min. For DAO formulated with CMS, the 100% was  0.45 ± 0.032 EU/mL sample,
0.41 ± 0.019 EU/mL sample for CMS:Chitosan or 0.40 ± 0.03 EU/mL sample for Chi-
tosan. n = 3.
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Fig. 4. Mono- and bi-enzymatic CMS:Chitosan formulations containing vegetal diamine oxidase (PSDAO) and/or catalase. Gastric stability in simulated gastric ﬂuid (SGF)
containing pepsin (0 and 60 min) of (a) PSDAO and (b) catalase as mono- and bi-enzymatic formulations based on CMS:Chitosan (1:1) and (c, d) their liberation in sim-



















c.39  ± 0.001 EU/mL sample) and of catalase (10% and 20% loading), formulated as m
0  min), was  considered as 100%. n = 3.
.3% to 50%, its residual enzymatic activity found inside the tablet
emained relatively constant (more than 80%) after 60 min  of SGF
ncubation, suggesting that the catalase can undergo a kind of self-
rotection by possible protein–protein interactions, in addition to
he relative protection afforded by the excipients (Fig. 3a). Thus,
ue to possible intra- and inter-chain protein associations, catalase
enerated an outer protective gel layer, preventing the gastric ﬂuid
ccess into the tablet. As found by the pH indicator test, the assay of
he enzyme activity showed that the formulation of 100% catalase
ablets (excipient-free) presented a relatively good stability in gas-
ric ﬂuid (60 min), with 63% catalase remaining enzymatic activity
er tablet (Fig. 3a). Differently, the free catalase solution (unformu-
ated) was almost totally degraded in the same conditions (data not
hown).Higher loading in catalase per tablet did not deliver higher per-
entages of catalase in SIF medium (Fig. 3b). Only the CMS:Chitosan
ormulation containing 10% catalase liberated more than 50%
atalase (enzymatic activity) after 480 min  of SIF incubation.nd bi-enzymatic CMS:Chitosan tablets, and determined in 50 mL phosphate buffer
Differently, for the catalase loadings between 20% and 100%, less
than 15% catalase enzymatic activity was released during the ﬁrst
480 min  in SIF (Fig. 3b). A certain ratio between catalase and poly-
meric excipients (CMS and Chitosan) should be kept to better
protect and to delay the catalase delivery over 8 h in SIF.
Physical properties of tablets might also affect the behavior
of formulations in simulated gastro-intestinal conditions. Tests of
crushing strength (hardness) and disintegration were performed on
similar protein formulations (monolithic tablets) based on similar
CMS, CMS:Chitosan (1:1, physical mixture) and Chitosan excipi-
ents (Assaad et al., 2011). Generally, the tablets containing protein
and the mentioned excipient(s) showed crushing strengths higher
than the excipient-free protein tablets, indicating that the presence
of excipient(s) favors the physical stabilization of tablets following
compression. There more, the presence of CMS  enhanced the crush-
ing strength of tablets from 128 N with Chitosan only to 176–179 N
with CMS:Chitosan mixture (Assaad et al., 2011). Regarding the
disintegration properties in various media, due to the solubility of
































































Fig. 5. Evaluation of diamine oxidase enzymatic activity in the presence of catalase.
Diamine oxidase (DAO) enzymatic activity was evaluated (a) by the peroxidase cou-
pled assay of the released H2O2 and (b) by glutamate dehydrogenase (GDH)  coupled
assay of the released NH3. The DAO enzymatic activity (%) was  evaluated at different
mass ratios (6:1, 2:1, 1:1) of vegetal DAO (PSDAO) and Catalase powders (contain-
ing 1:3, 1:10, 1:20 PSDAO:Catalase protein ratios), which were dissolved in 50 mL
phosphate buffer solution (pH 7.0). The enzymatic activities of PSDAO, determined in
phosphate buffer by peroxidase coupled assay (12.81 ± 0.27 EU/mg protein) and by
GDH coupled assay (13.15 EU/mg protein), in absence of catalase, were considered
as  100%. n = 3.
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hitosan in an acidic medium, the disintegration time was  shorter
or the formulations containing higher amount of Chitosan (Assaad
t al., 2011). The longest disintegration time was shown by CMS
ue to the stabilization of its chains by carboxyl groups in an acidic
edium. In a simulated intestinal medium, the tablets based on
MS, CMS:Chitosan mixture or Chitosan showed a disintegration
ime of about 60–70 min, the disintegration time in an intestinal
uid being shorter for each mentioned formulation than that in a
astric medium (Assaad et al., 2011). Due to the fact that Chitosan
annot form a hydrogel in a neutral medium, the tablets based on
hitosan present a low cohesion between the particles, resulting in
 faster disintegration in an intestinal medium.
In order to reduce the amount of the hazardous H2O2 by-product
f DAO, the catalase, as second therapeutic enzyme, was added
o the PSDAO formulation based on CMS:Chitosan. The presence
f catalase in the PSDAO formulation diminished the determined
AO remaining enzymatic activity inside the tablet after 60 min
f SGF incubation, either for 10% or 20% catalase when detected
ith the glutamate dehydrogenase coupled assay (Fig. 4a). A reduc-
ion of remaining catalase activity, after 60 min  in SGF, was  also
bserved for the formulations containing the PSDAO (Fig. 4b). For
he bi-enzymatic formulations with CMS:Chitosan, the presence of
0% or 20% catalase did not signiﬁcantly modify the DAO libera-
ion (Fig. 4c). Differently, for the same formulations, the presence
f 20% PSDAO preparation increased the catalase synchronously
iberated in SIF medium (Fig. 4d). Thus, the presence of PSDAO
n the bi-enzymatic formulations contributed to a better libera-
ion of catalase, probably, due to the presence of phosphates in
he PSDAO vegetal extract which enhance the dissolution. The
MS:Chitosan formulation containing 20% PSDAO:10% Catalase lib-
rated more catalase than the bi-enzymatic formulation containing
0% PSDAO:20% Catalase, where the protein–protein interactions
ere probably more representative.
Using the peroxidase coupled assay, an apparent decrease of
AO enzymatic activity was obtained in the presence of catalase
n function of PSDAO:Catalase ratios (Fig. 5a), due to the diminu-
ion of released H2O2 (substrate for catalase). Differently, using the
DH coupled assay, the DAO enzymatic activity was found constant
Fig. 5b) for the same PSDAO:Catalase ratios, because the assay
easures speciﬁcally NH3 and not H2O2, showing that the DAO
nzymatic activity is not affected by the presence of catalase.
Vegetal DAO enzyme presents a high speciﬁcity for primary
iamines and histamine, catalyzing their oxidation to correspond-
ng aldehyde, H2O2 and NH3. In the presence of putrescine
s substrate for DAO, the OPDA, as co-substrate of peroxi-
ase (Calinescu et al., 2010), is oxidized into a colored product
azo-aniline) by the released H2O2, under peroxidase catalysis
Scheme 1a). When catalase is synchronously released, it will
ecompose H2O2 released from DAO enzymatic activity, resulting
n a decrease of the azo-aniline product of the peroxidase reac-
ion. This alters the DAO dosage and apparently decreases the
easured DAO activity (Scheme 1a). When determined by the
DH coupled assay (speciﬁc for NH3 and not for H2O2), the DAO
nzymatic activity remained constant for all the tested ratios of
SDAO:Catalase (Scheme 1b). The DAO enzymatic activity consists
n oxidation of putrescine in the presence of dissolved O2 (the two
ubstrates of DAO). When catalase is also added in solution (dif-
erent ratios of PSDAO:Catalase), part of H2O2 produced by DAO
ill be decomposed by catalase generating, thus, some supple-
entary O2, which is expected to enhance the rate of substrate
histamine, putrescine) oxidation and even to shift the equilib-
ium in favor of the reaction products. From the apparent decrease
f DAO enzymatic activity in the presence of catalase, it is possi-
le to determine the number of moles of H2O2 decomposed by
atalase. Consequently, from differences between DAO enzymatic
ctivity of PSDAO alone and at different ratios PSDAO:Catalase, itScheme 1. Representation of the enzymatic coupled reactions of diamine oxidase
(DAO). (a) Peroxidase coupled assay, speciﬁc for released H2O2 and (b) glutamate
dehydrogenase (GDH) coupled assay, speciﬁc for released NH3.
is possible to estimate the additional O2 produced by catalase in
our in vitro study (0.0115, 0.0185 and 0.026 moles O2/10 min/mL
reactional medium, at 37 ◦C). The concentration of O2 currently dis-
solved in water at 37 ◦C is of about 0.212 moles O2/mL, which is in
excess compared with the O generated from the catalase activity.2
Thus, the amount of additional O2 produced by H2O2 decomposi-
tion seems not high enough to enhance the DAO enzymatic activity,
which remained constant in the presence of catalase. However, the
C. Calinescu et al. / International Journal o
Fig. 6. In vitro evaluation of the bi-enzymatic formulation based on CMS:Chitosan.
Enzymatic activity of diamine oxidase (DAO) released in simulated intestinal ﬂuid
(SIF  with pancreatin), determined (a) by the peroxidase coupled assay, speciﬁc for
the released H2O2, and (b) by the glutamate dehydrogenase coupled assay, speciﬁc






























Beaven, M.A., 1982. Factors regulating availability of histamine at tissue receptors.0 min  in simulated gastric ﬂuid (SGF with pepsin), followed by incubation in SIF,
t  50 rpm and 37 ◦C. Substitution degree of CMS: 0.126. n = 3.
ssociation of catalase to DAO and their simultaneously release is
upposed to be therapeutically beneﬁcial in IBD treatment, since
he volume of available ﬂuid in the colon is reduced and the O2
vailability is scarce. Thus, additional low amounts of O2 will prob-
bly be efﬁcient for DAO activity.
The DAO liberation in SIF from the PSDAO:Catalase bi-enzymatic
MS:Chitosan tablets, evaluated with the peroxidase coupled assay,
howed an apparent reduction of released DAO measured activ-
ty, more accentuated for the formulation containing a higher
oading of catalase (20% PSDAO:20% Catalase) compared to the
ono-enzymatic formulation containing 20% PSDAO only (Fig. 6a).
hen DAO liberation in SIF was determined by the GDH cou-
led assay (speciﬁc for the NH3 released), no signiﬁcant differences
ere obtained between the mono-enzymatic PSDAO formulation
nd the bi-enzymatic formulations containing 10% or 20% catalase
Fig. 6b). The capacity of our bi-enzymatic CMS:Chitosan formu-
ations to produce and to decompose H2O2, investigated with the
wo DAO enzymatic assays (Scheme 1), conﬁrmed that the appar-
nt decrease of DAO enzymatic activity, determined via peroxidase
ssay, was due to the decomposition of H2O2 by catalase liber-
ted from the tablets almost in the same time with DAO. Using
he GDH coupled assay, there were no differences between the
ctivities of the released DAO formulated alone (20% loading) or as
i-enzymatic formulations, conﬁrming the results obtained before
ith different ratios of the two non-formulated free enzymes. Thisact is important, because, when the bi-enzymatic formulation is
dministrated in vivo, the released DAO will locally degrade the
istamine (endogenous, from intestinal inﬂammatory reactions,f Pharmaceutics 428 (2012) 48– 56 55
or exogenous, from food) and will produce H2O2, a pro-oxidant
with damaging effects. Therefore, the catalase will be beneﬁcial,
particularly when locally liberated simultaneously with DAO, to
decompose the H2O2 from histamine catabolism or from other
inﬂammatory process. The DAO appears as a bi-functional enzyme:
(i) histaminase, with an amine oxidase activity controlling the
level of biogenic amines, decomposing the pro-inﬂammatory his-
tamine, and (ii) antioxidant, scavenging the pro-oxidant oxidative
species. The presence of catalase in our mono- and bi-enzymatic
CMS:Chitosan formulations has also several roles: (i) to protect
DAO against H2O2 damages and to improve the stability of the for-
mulations in simulated gastro-intestinal conditions, (ii) to afford a
certain gastro-protection, based on a kind of self-stabilization by
protein–protein interactions within the tablets, (iii) to reduce the
amount of the hazardous H2O2, a pro-oxidant produced from DAO
activity or from other inﬂammatory reactions.
To prevent systemic effects of histamine, rapid and efﬁ-
cient clearance from blood is vital. When the capacity for
local histamine elimination is unbalanced, it can return, via
Organic Cation Transporters (OCT), into the systemic circulation
and generate deleterious elevations in plasma histamine level
(Aschenbach et al., 2009). Oral administration of histaminase
formulated with CMS  and Chitosan will decrease the level of
histamine in the intestinal lumen, will prevent readsorption via
OCT and will enhance histamine bioelimination. In this context,
the bi-enzymatic PSDAO:Catalase formulation with CMS:Chitosan
excipients could be an alternative for a better control of the
inﬂammation and related deleterious effects occurred in the
inﬂammatory bowel diseases.
4. Conclusion
This study showed the potential of the CMS:Chitosan formula-
tions to protect PSDAO and/or Catalase against simulated gastric
conditions and to control their release in simulated intestinal
ﬂuid. Tablets loaded with PSDAO:Catalase are expected to improve
the treatment of inﬂammatory enteric diseases by reducing local
inﬂammation through accelerated histamine catabolism and by
preventing free radical-mediated tissue injury. A possible ther-
apeutic effect of DAO could also be expected in pseudo-allergic
diseases, due to the elimination of histamine excess in intestinal
lumen, and in intestinal tumors, due to the anti-neoplastic prop-
erties of amine oxidases. Our proposed formulations may open the
way  to innovative and non-toxic bi-functional enzyme therapeutic
approaches for intestinal diseases.
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